Pages
DCHS Chair Julie visits Okeover Ward
https://dchs.nhs.uk/my_dchs/show-me/staff-news-my-download/dchs-chair-julie-visits-okeover-ward
Files
Disclosure Ref 2024236 - Weight loss drug.pdf
Freedom of Information request reference 2024236 relating to GP & A&E appointments and deaths relating to overdose of either Saxenda, ozempic or wegovy (medical names Liraglutide and semaglutide) weightloss drugs
Disclosure Ref 2024195 - Financial spend on agency staff.pdf
Freedom of information disclosure reference 2024195 relating to financial spend on agency staff for the most recent month
Disclosure Ref 2025183 - Child Exploitation including staff safeguarding training & referrals.pdf
Disclosure Ref 2025183 relating to Child Exploitation including staff safeguarding training & referrals
Disclosure Ref 2024256 - Cost Improvement Plans 2024 - 2025.pdf
Freedom of information disclosure relating to the Trusts total planned CIP/efficiency savings for 2024 - 2025 and the CIP/efficiency plan for 2024-25 as a % of operating expenses
Disclosure ref 2024248 - Fire systems (1 of 2).pdf
Freedom of information disclosure relating to fire alarm system maintenance and contract in place
Long Term Segregation Policy (P86)
This policy aims to provide clear guidance on the use of long term segregation, (please note the use of seclusion is covered in DCHS trust policy – (Management, Prevention and reduction of violence and aggression including physical restraint and seclusion). To ensure restrictive interventions remain proportionate, least restrictive, take account of patient preference where possible, and last for no longer than is necessary. The policy sets clinical standards to ensure compliance with the Mental Health Act 1983 and subsequent Code of Practice 2015 alongside NICE guidance NG10. To ensure robust governance arrangements that are transparent in their nature. To support the trusts ambition of reducing the use of restrictive practices. The policy aims to ensure the specific needs of all patients are met in a fair and equitable way.
FINAL Chief Executive Designate - Stakeholder Briefing - 11 November 2021.pdf
Dr Chris Clayton appointment; Chief Executive JUCD
Standard Operating Procedure for the Issue of Procaine Penicillin outside of ISHS services (S83)
This SOP sets out the actions which should be taken to facilitate the administration of the procaine penicillin outside of ISHS opening hours.
DCHS Safeguarding Supervision Policy (P15)
Safeguarding supervision is recognised by DCHS FT as an important element within clinical supervision and the safety culture. In addition to an individual’s knowledge, skills, experience and training, effective safeguarding practice relies on a professional’s curiosity and vigilance. Safeguarding supervision provides an opportunity to both sustain and foster these qualities and ensure staff are updated on current safeguarding issues, legislation and outcomes of recent Child Practice Reviews (CPR), Serious Incident Learning Reviews (SILR), Domestic Homicide Reviews (DHR), and Safeguarding Adult Reviews (SAR). This policy covers both Adult and Children
Intravenous Therapy and Vascular Access Device (VAD) Policy - Adults (P47)
The use of intravenous medicines has many healthcare benefits for patients. Intravenous medicines are increasingly commonplace within the community setting and the need for an intravenous medicine is often a reason for patient’s being admitted to secondary care. Following the implementation of national and local policy, there is a new direction for community care providers such as DCHS to develop services that can be provided within the community hospital or community setting to accommodate patient’s being able to receive more complex care. The aims of this policy are: To prevent unnecessary acute hospital admission and to facilitate early discharge from the acute hospital setting by enabling patients to receive IV medicines safely within their own home or a community health care setting. To ensure an IV medicine is the most appropriate treatment for the patient and that it is administered via the most appropriate Vascular Access Device, the most appropriate vascular access site is chosen and the IV medicine is administered at the right time. To reduce the risk of complications by ensuring registered practitioners’ practice safely and consistently in relation to the administration of IV medicines, Vascular Access Device Insertion and the care and maintenance of Vascular Access Devices (VADs), through the implementation of evidence-based practice and by providing staff with the necessary guidance on clinical practice and training. To preserve and promote patient vessel health in the short and long term by ensuring any Vascular Access Device inserted is the most appropriate device for the treatment being administered and that it is placed by the most appropriately qualified practitioner.